I-Corps: Establishing an innovation ecosystem for technology transition of MEMS-based drug infusion pumps

I-Corps：建立MEMS药物输注泵技术转型创新生态系统

• 批准号: 1157852
• 负责人: Ellis Meng
• 金额: $ 5万
• 依托单位: University of Southern California
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-10-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1157852&HistoricalAwards=false
• 关键词: Corps; Establishing; innovation; ecosystem; technology

The pump proposed in this I-Corps effort addresses critical unmet needs by providing a miniaturized mouse-compatible form factor, wireless power and remote control features, and fully-customizable dosing capability for chronic drug administration studies. The team addresses the immediate need from academia and industry for pumps in both laboratory animal research for scientific discovery and preclinical drug studies. Applying the pump technology at the earliest stage of preclinical validation may improve the development of new drugs and enable new treatment paradigms. The scalability of the technology also has the potential to extends the addressable market beyond laboratory animal research to human patient care, The long-term goal is to leverage this technology in combination with novel therapeutics that cannot be delivered by other means to provide patient-specific dosing profiles in humans in a manner that maximizes therapeutic benefit while minimizing side effects. This I-Corps effort will result in a plan to transition the proposed innovation to the marketplace, fabrication of prototypes, and technology demonstration.This project seeks to transition innovative technology, a miniature implantable infusion pump, for drug development and treatment. The pump specifically addresses limitations of current technologies and offers accurate and customizable dosing in a compact form factor. The technology incorporates next generation capability through the integration of wireless communication and information technology. These advanced delivery systems and novel therapeutics present a fertile opportunity for advancing not only research but technology commercialization and health care outcomes.

I-Corps在这项工作中提出的泵通过提供小型化的小鼠兼容外形、无线电源和远程控制功能以及完全可定制的长期给药研究给药能力来解决关键的未满足需求。该团队解决了学术界和工业界对泵的迫切需求，用于科学发现的实验室动物研究和临床前药物研究。在临床前验证的最早阶段应用泵技术可以改善新药的开发并实现新的治疗模式。该技术的可扩展性还具有将可寻址市场从实验室动物研究扩展到人类患者护理的潜力，长期目标是利用该技术与无法通过其他方式递送的新型治疗剂组合，以最大化治疗益处同时最小化副作用的方式在人体中提供患者特异性给药曲线。这个I-Corps的努力将导致一个计划，将拟议的创新转化为市场，原型的制造和技术演示。该项目旨在将创新技术，微型植入式输液泵，用于药物开发和治疗。该泵专门解决了当前技术的局限性，并以紧凑的外形提供精确和可定制的剂量。该技术通过无线通信和信息技术的集成，结合了下一代能力。这些先进的输送系统和新型疗法不仅为推进研究，而且为技术商业化和医疗保健成果提供了丰富的机会。